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Abstract
Background:  Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are
reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect
of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX
4042, in in vitro and in vivo human colon cancer models and investigated the mechanisms of action
underlying its antitumor activity.
Methods: In vitro cytotoxicity was evaluated on a panel of colon cancer lines (LoVo, LoVo Dx,
WiDr and LRWZ) by sulforhodamine B assay. Cell cycle perturbations and apoptosis were
evaluated by flow cytometry. Protein expression was detected by Western blot. In the in vivo
experiments, tumor-bearing mice were treated with NCX 4040, five times a week, for six
consecutive weeks.
Results: In the in vitro studies, aspirin and NCX 4042 did not induce an effect on any of the cell
lines, whereas NCX 4040 produced a marked cytostatic dose-related effect, indicating a pivotal
role of the -NO2 group. Furthermore, in LoVo and LRWZ cell lines, we observed caspase-9 and -
3-mediated apoptosis, whereas no apoptotic effect was observed after drug exposure in WiDr or
LoVo Dx cell lines. In in vivo studies, both NCX 4040 and its parental compound were administered
per os. NCX 4040 induced a 40% reduction in tumor weight. Conversely, aspirin did not influence
tumor growth at all.
Conclusions: NCX 4040, but not its parental compound, aspirin, showed an in vitro and in vivo
antiproliferative activity, indicating its potential usefulness to treat colon cancer.
Background
One of the most important approaches for reducing can-
cer incidence is chemoprevention. This is especially rele-
vant for colon cancer, which represents the third leading
cause of cancer mortality in developing countries and for
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which diagnostic tests and clinical treatments are not sat-
isfactory [1].
Recently published reviews [2-4] underline the growing
role of nonsteroidal antiinflammatory drugs (NSAIDs) in
preventing colon cancer. Epidemiologic studies [5] have
found that long-term users of aspirin or other NSAIDs
have a lower risk of colorectal adenomatous polyps and
colorectal cancer compared to nonusers. Randomized
clinical trials have confirmed that two NSAIDs, sulindac
[6-9] and the selective cyclooxygenase (COX)-2 inhibitor,
celecoxib [10], effectively inhibit the growth of adenoma-
tous polyps and cause regression of existing polyps in
patients with familial adenomatous polyposis (FAP),
although a recent study showed very clear benefits only
for the first six months of treatment with sulindac [11].
Despite a multiplicity of studies conducted on this com-
pound family of drugs, little is known about the molecu-
lar targets that are responsible for their tumor-preventing
properties and which are important, not only from a
mechanistic point of view, but also because of their clini-
cal implications in identifying individuals or subsets of
patients who are sensitive to these drugs. Originally, it was
believed that the regular use of these compounds acted
exclusively through the inhibition of COX-1 and COX-2
activity involved in the production of prostaglandins [12].
There is now mounting evidence that the chemopreven-
tive action of NSAIDs may involve COX-independent
mechanisms [13,14]. Furthermore, despite initial enthusi-
asm about the potential relevance of NSAIDs, especially
the selective COX-2 inhibitors, their use as chemopreven-
tive or anticancer agents has been greatly limited by side-
effects on gastrointestinal and renal systems.
In an attempt to reduce gastrointestinal toxicity, conven-
tional NSAIDs have been coupled with a nitric oxide
(NO)-releasing moiety [15,16]. The rationale for this
approach is that NO compensates for the functions of
prostaglandins, which are inhibited by conventional
NSAIDs, in the gastrointestinal tract. Both prostaglandins
and NO are capable of enhancing mucosal blood flow,
mucus release and repair of mucosal injury in humans
[17-19] and of reducing the severity of gastric injury in
experimental models [16].
Interestingly, the activity of some NO-NSAIDs is consider-
ably higher than that of the parental drugs. For example,
NCX 4016 has been found to be much more effective than
the parent aspirin in reducing aberrant crypt foci, a pre-
cancerous lesion, in a rat model of colorectal cancer [20]
and in inducing cell perturbations and growth inhibition
in a panel of colorectal cancer cell lines in vitro [21]. Sim-
ilarly, Williams et al. [22,23], in another panel of human
colon cancer lines, reported a higher antiproliferative
activity of NO-NSAID compounds compared to the par-
ent aspirin.
In the present work, we compared the effect of a novel
NO-releasing derivate, NCX 4040, with that of aspirin and
its denitrated analog in in vitro and in vivo human colon
cancer models and investigated the mechanisms of action
underlying its antitumor activity.
Materials and methods
In vitro studies
Cell lines
The studies were performed on colon adenocarcinoma
cell lines: 2 (LoVo and WiDr) were obtained from the
American Type Culture Collection (Rockville, MD), 1
(LRWZ) was isolated in our laboratory and derived from
a patient with a confirmed diagnosis of colon adenocarci-
noma, and 1 was doxorubicin-resistant (LoVo Dx) derived
from the above-mentioned LoVo cells. Cell lines were
maintained as a monolayer at 37°C and subcultured
weekly. Culture medium was composed of DMEM/HAM
F12 (1:1) supplemented with fetal calf serum (10%),
glutamine (2 mM), non-essential aminoacids (1%) (Mas-
cia Brunelli s.p.a., Milan, Italy), and insulin (10 µg/ml)
(Sigma Aldrich, Milan, Italy). Cells were used in the expo-
nential growth phase in all the experiments.
Drugs
Aspirin, NCX 4040 (NO-releasing aspirin), NCX 4042
(denitrated analog of NCX 4040) (Fig. 1), (all supplied by
NicOx S.A., Sophia Antipolis, France), Z-LEHD-FMK (cas-
pase-9 inhibitor) (BD Biosciences Pharmingen, Milan,
Italy), sodium nitroprusside dihydrate and S-nitroso-N-
acetylpenicillamine (NO donors) (Sigma Aldrich) were
solubilized in dimethylsulfoxide (DMSO) (Sigma
Aldrich) and freshly diluted in culture medium before
each experiment. The final DMSO concentration never
exceeded 1% and this condition was used as control in
each experiment.
Chemosensitivity assay
Sulforhodamine B (SRB) assay was used according to the
method by Skehan et al [24]. Briefly, cells were collected
by trypsinization, counted and plated at a density of
10,000 cells/well in 96-well flat-bottomed microtiter
plates (100 µl of cell suspension/well). In the chemosen-
sitivity assay, NCX 4040, NCX 4042 and aspirin were
tested at scalar concentrations ranging from 1 to 100 µM
for 24 h and 48 h or for 24 h and 48 h followed by a 24-
h culture in drug-free medium. Experiments were run in
octuplet, and each experiment was repeated three times.
The optical density of treated cells was determined at a
wavelength of 540 nm by means of a fluorescence plate
reader. Growth inhibition and cytocidal effect of drugs
were calculated according to the formula reported byJournal of Translational Medicine 2005, 3:7 http://www.translational-medicine.com/content/3/1/7
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Monks et al. [25]: [(ODtreated - ODzero)/(ODcontrol -
ODzero)] × 100%, when ODtreated is > to ODzero. If
ODtreated is below ODzero, cell killing has occurred. The
ODzero depicts the cell number at the moment of drug
addition, the ODcontrol reflects the cell number in
untreated wells and the ODtreated reflects the cell
number in treated wells on the day of the assay.
Western blot
The cells were treated according to the previously
described Western blot procedure. [26] COX-1 antibody
(polyclonal C-20, dilution 1:100) was purchased from
Santa Cruz-Biotechnology (Santa Cruz, CA), COX-2
(monoclonal C22420, dilution 1:250) from Transduction
Laboratories (Lexington, KY), and caspases-3 and -9 (pol-
yclonal antibodies, dilution 1:500) from Cell Signaling
Technology, Inc. (Beverly, MA).
RT-PCR
Total RNA was isolated from cells by direct lysis and quan-
tified spectrophotometrically. After quantification, RT
reaction was performed with 1 µg of each sample using
Gene Amp Gold RNA PCR Core Kit (Perkin Elmer Biosys-
tems, Milan, Italy). The same cDNA was used for RT-PCR
amplification of COX-1 and COX-2. PCR reactions were
carried out in a final volume of 25 µl containing 2 µl of
cDNA template, 1 unit of Klen Taq, 0.2 mM dNTP and
0.4-µM amounts of each forward and reverse primer,
using a thermal cycler (PTC 200, Genenco, Florence,
Italy). 5-µl aliquots of the amplified DNA fragments were
separated on an ethidium bromide-stained 2% agarose
gel.
Cell cycle distribution
After a 24-h exposure to 10 µM of NCX 4040, cells were
harvested and stained in a solution containing RNase (10
Kunits/ml; Sigma Aldrich) and NP40 (0.01%; Sigma
Aldrich). After 30–60 min, samples were analyzed by flow
cytometry using a FACS Vantage flow cytometer. Data
acquisition (10,000 events were collected for each sam-
ple) was performed using CELLQuest software. Data were
elaborated using Modfit (DNA Modelling System) soft-
ware and expressed as fractions of cells in the different
cycle phases. Samples were run in triplicate, and each
experiment was repeated three times.
Apoptosis
Apoptosis was evaluated by flow cytometric analysis
according to the previously described TUNEL assay proce-
dure [26]. Briefly, after a 24- and 48-h exposure to 5, 10
and 50 µM of NCX 4040, cells were trypsinized, fixed,
exposed to TUNEL reaction mixture and counterstained
with propidium iodide before FACS analysis.
In LoVo cells, positivity to TUNEL assay was also evalu-
ated by fluorescence photomicroscope (Zeiss, Axioscope
Chemical structure and molecular weight (m.w.) of traditional aspirin, its NO-derivative, NCX 4040, and the NCX 4040 deni- trated analog, NCX 4042 Figure 1
Chemical structure and molecular weight (m.w.) of traditional aspirin, its NO-derivative, NCX 4040, and the NCX 4040 deni-
trated analog, NCX 4042.
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40) according to the manufacturer's instructions (In situ
cell death detection kit, fluorescein; Roche Diagnostic
GmbH, Mannheim, Germany).
Finally, the cell-permeable DNA dye 4',6-DAPI and a flu-
orescence photomicroscope (Zeiss, Axioscope 40) were
used to visualize chromatin condensation and/or frag-
mentation typical of apoptotic cells.
In vivo studies
Animals
Antitumor efficacy was evaluated on 6–8-week old CD-1
male nude (nu/nu) mice weighing 22–24 g (Charles River
Laboratories, Calco, Italy). All procedures involving ani-
mals and their care were conducted in conformity with
institutional guidelines, which are in compliance with
national (D.L. No. 116, G.U., Suppl. 40, Feb. 18, 1992;
Circolare No. 8, G.U., July 1994) and international laws
(EEC Council Directive 86/609, OJ L 358. 1, Dec 12,
1987; Guide for the Care and Use of Laboratory Animals,
United States National Research Council, 1996).
Drugs
NCX 4040 and aspirin were homogeneously suspended in
0.5% carboxymethyl cellulose (CMC) containing 10% of
DMSO for antitumor efficacy studies. All the drugs were
administered orally.
Antitumor efficacy
Since LRWZ line showed a low tumorigenicity when cells
were injected into nude mice, in vivo experiments were
performed on WiDr, LoVo and LoVo Dx lines. Tumor cells
were resuspended (5 × 106 viable cells) in 0.2 ml of serum-
free medium and injected into the hind leg muscles of
mice.
Each experimental group included at least 6 mice. 10 mg/
kg of aspirin and NCX 4040 were administered orally five
days a week for 6 consecutive weeks starting on the 6th day
after the tumor cell implant, when a tumor mass of about
300 mg was evident in all the animals. The dose of aspirin
and NCX 4040 was chosen on the basis of previous obser-
vations obtained using the parental NCX 4016 compound
[27]. Toxicity of treatments was evaluated in terms of
body weight loss and drug deaths. The tumor weight was
calculated from caliper measurements according to the
method of Geran et al. as previously reported [28]. The
antitumor efficacy of treatments was assessed by the fol-
lowing endpoints: a) percent tumor weight inhibition
(TWI%), calculated as [1-(mean tumor weight of treated
mice/mean tumor weight of controls)] × 100; b) tumor
growth delay, evaluated as T – C, where T and C are the
median times for treated and control tumors, respectively,
to achieve equivalent size.
The significance of results was analyzed by the Mann-
Whitney non parametric test. Differences were considered
significant at P values < 0.05 (two-sided).
Results
In vitro studies
The effect of aspirin, NCX 4040, and its structural analog,
NCX 4042, on cell growth was determined after different
exposure schemes and using various concentrations. Aspi-
rin and NCX 4042 did not exhibit an effect on any of the
cell lines (Fig. 2). In contrast, NCX 4040 showed both
cytostatic and cytocidal effects, as evaluated by Monk's
model (Fig. 3). In particular, the highest cytostatic effect
was observed after a 24-h drug exposure followed by a 24-
h washout, with a 50% growth inhibition (GI50) ranging
from 5.4 µM in LoVo cells to 24 µM in LoVo Dx. The same
treatment scheme also induced the highest cytocidal
effect, with a modulation for the different cell lines and a
50% lethal concentration (LC50) in LoVo cells (9.6 µM)
about four- and threefold lower than that observed in
WiDr and LRWZ, respectively. In LoVo Dx, no cytocidal
effect was observed at any of the concentrations tested.
Flow cytometric analysis of apoptosis performed after
exposure to various concentrations of NCX 4040 showed
90% of apoptotic cells at 24 h starting from a 10-µM con-
centration in LoVo line, whereas apoptosis was not
detected at the same time in any other cell line at any of
the concentrations tested (Table 1). After a 48-h exposure,
apoptosis was also induced in LRWZ cells, albeit to a
lesser degree, at 10-µM (20%) and 50-µM (60%)
concentrations.
In LoVo cells, which proved to be the biological system
most sensitive to NO-aspirin, the induction of apoptosis
produced by a 10-µM concentration was analyzed as a
function of time. The results showed that the production
of apoptotic cells is time-dependent, reaching as much as
80% after a 16-h drug exposure (Fig. 4A). Apoptotic ele-
ments were clearly visible using the in situ TUNEL analysis
(Fig. 4B) and at fluorescent microscopic examination of
cells stained with DAPI nuclear dye (Fig. 4C). Further-
more, cell death was strongly inhibited by simultaneous
exposure of LoVo cells to a 10-µM concentration of NCX
4040 and a 100-µM concentration of caspase-9 inhibitor
(Fig. 4D). Similar findings were obtained after exposure to
caspase-3 inhibitor (data not shown).
To understand the mechanisms responsible for the induc-
tion or lack of apoptosis in the different cell lines, we
explored the modulation of COX-2 expression and the
activation of caspases-3 and -9, which are involved in the
mitochondrial pathway of apoptosis.Journal of Translational Medicine 2005, 3:7 http://www.translational-medicine.com/content/3/1/7
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All the cell lines used were positive for the presence of the
isoenzymatic form COX-1, as evaluated by mRNA and
protein expression (Fig. 5A). Furthermore, after a 24-h
exposure to NCX 4040, the COX-1 expression level
remained unchanged in all the cell lines (Fig. 5B). COX-2
mRNA and protein expression were both observed in
WiDr and LoVo Dx cell lines, whereas neither was
detected in LRWZ, and only mRNA was observed in LoVo
cells. Furthermore, in WiDr and LoVo Dx cells, no change
was observed in the COX-2 protein expression level after
a 24-h exposure to NCX 4040 or a 24-h exposure followed
by a 24-h washout (Fig. 5C).
Although all 4 lines basally expressed the 2 caspases (data
not shown), these proteases were activated only in LoVo
and in LRWZ cells, where apoptosis was found. In partic-
ular, in LoVo cells caspase-3 and -9 activation was already
evident after 3 h, whereas in LWRZ, activation took a
longer time to occur (at least 10 h for caspase-9 and 12 h
for caspase-3). The temporal activation in these 2 cell lines
corresponds to the early or late induction of apoptosis
(Fig. 6A,6B).
In vivo studies
The administration of aspirin in mice bearing all 3 cell
lines did not influence the growth of tumors (Fig.
7A,7B,7C). In contrast, treatment with NCX 4040 was
effective in the different cell lines employed, with a reduc-
tion of about 40% in the tumor mass (P < 0.001), evalu-
ated at the nadir of the effect, compared to untreated and
Antiproliferative and cytocidal activity of aspirin and NCX 4042 at concentrations of 1, 5, 10, 50 and 100 µM Figure 2
Antiproliferative and cytocidal activity of aspirin and NCX 4042 at concentrations of 1, 5, 10, 50 and 100 µM. Exposure time to 
drugs:, 24 h; , 24 h + 24-h washout; ❍ , 48 h; ▲ , 48 h + 24-h washout. Each point indicates the mean of at least three experi-
ments and SD never exceeded 5%.
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aspirin-treated groups. A difference in NCX 4040
sensitivity was also evident between the lines. Tumor
regrowth was observed after 8 and 11 days for LoVo Dx
and WiDr lines, respectively. Conversely, inhibition of the
tumor mass for LoVo tumors was maintained from day 15
to day 30 following the injection of tumor cells and a
Cytotoxic activity of NCX 4040 after 24-h exposure followed by 24-h washout Figure 3
Cytotoxic activity of NCX 4040 after 24-h exposure followed by 24-h washout. , 24 h + 24 h-washout. The two drugs were 
used at concentrations of 1, 5, 10 and 50 µM. Each point indicates the mean of at least three experiments; SD never exceeded 
5%.
Table 1: Apoptotic cells after a 24- or 48-h exposure to various concentrations of NCX 4040
Cell Line 24 h 48 h
5 µM 10 µM5 0   µM5   µM1 0   µM5 0   µM
LoVo Dx 0.7 ± 0.01 0.5 ± 0.01 0.5 ± 0.02 0.5 ± 0.0 0.02 ± 0.01 0.2 ± 0.0
WiDr 1.0 ± 0.01 4.0 ± 0.1 1.0 ± 0.05 2.0 ± 0.03 5.0 ± 0.02 5.0 ± 0.03
LRWZ 3.0 ± 0.03 5.0 ± 0.02 4.0 ± 0.1 4.0 ± 0.01 21.0 ± 0.3 60.0 ± 1.3
LoVo 2.0 ± 0.05 90.0 ± 2.3 n.e.* 3.0 ± 0.02 n.e. n.e.
* n.e.: not evaluated
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tumor growth delay of 19 days was observed (P < 0.001).
These results are in agreement with the in vitro data, which
demonstrated that LoVo line is the most sensitive to NCX
4040 exposure.
Discussion
Our study evaluated the antitumor activity of the novel
NO-aspirin NCX 4040 in vitro on a panel of human colon
cancer lines with different genetic profiles representing
clinical tumor heterogeneity, and in vivo on xenografted
immunosuppressed mice.
Neither aspirin nor the denitrated analog, NCX 4042,
influenced the growth of any of the cell lines studied,
whereas NCX 4040 produced an important cytocidal
effect. These findings suggest a pivotal role of the -NO2
group in the mechanism of action underlying its in vitro
activity. Extensive evidence indicates that nitric oxide is
capable of initiating apoptotic cell death in some cell
types as a consequence of DNA-induced damage [29,30],
but the pathways involved are still not fully understood.
In the present study, it was seen that NCX 4040 induced
apoptosis in two (LoVo and LRWZ) of the four cell lines
investigated, albeit with a modulated activity. In
particular, we observed early apoptosis in LoVo cells start-
ing from a 6-h drug exposure, with a peak after 20 h, as
shown by the TUNEL assay. We found that apoptotic
(A) Percentage of apoptosis in LoVo cells after exposure times of 4, 8 12, 16, 20 and 24 h to 10 µM of NCX 4040 Figure 4
(A) Percentage of apoptosis in LoVo cells after exposure times of 4, 8 12, 16, 20 and 24 h to 10 µM of NCX 4040. (B) Apopto-
sis in LoVo cells after a 24-h exposure as evidenced by in situ TUNEL assay. (C) Apoptosis in LoVo cells after a 24-h exposure 
as evidenced by DAPI staining. (D) Inhibition of NCX 4040-induced apoptosis in LoVo cells after a 24-h simultaneous exposure 
to the NO-NSAID and the caspase-9 inhibitor, as evidenced by TUNEL assay.
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death was induced by the concomitant activation of cas-
pases-9 and -3 a few hours after NCX 4040 exposure.
In LRWZ cells, a relevant apoptosis was also observed but
after a longer exposure time and at higher NCX 4040 con-
centrations, after which the irreversibly damaged cells
underwent apoptotic death through the activation of cas-
pases-9 and -3.
Moreover, two NO donors were used to better clarify the
role of the aspirin component. These compounds, at con-
centrations similar to those utilized for NCX 4040,
showed a very modest cytotoxic activity (data not shown),
confirming the importance of the aspirin component for
the antineoplastic effectiveness of the NCX 4040
molelcule.
In addition, WiDr and LoVo Dx cell lines, which proved
to be resistant to NCX 4040-induced apoptosis, were
(A) COX-1 and COX-2 basal mRNA and protein expression in the different cell lines Figure 5
(A) COX-1 and COX-2 basal mRNA and protein expression in the different cell lines. Lane a, LoVo cells; lane b, WiDr cells; 
lane c, LRWZ cells; lane d, LoVo Dx. (B) COX-1 protein expression in the different cell lines. LoVo: lane 1, untreated cells; lane 
2, cells exposed to 10 µM of NCX 4040 (24 h); LoVo Dx: lane 3, untreated cells; lane 4, cells exposed to 50 µM of NCX 4040 
(24 h); WiDr: lane 5, untreated cells; lane 6, cells exposed to 50 µM of NCX 4040 (24 h); LRWZ: lane 7, untreated cells; lane 8, 
cells exposed to 50 µM of NCX 4040 (24 h). (C) COX-2 protein expression in WiDr and LoVo Dx cell lines after different 
exposure schemes to 10 µM of NCX 4040. Lane 1, untreated cells (24 h); lane 2, NCX 4040 (24 h); lane 3, untreated cells (24 
h) + washout (24 h); lane 4, NCX 4040 (24 h) + washout (24 h).
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characterized by baseline expression of COX-2 protein.
This finding, which is consistent with data recently pub-
lished for breast and colorectal cancer cells, would seem to
support the hypothesis that a high level of COX-2 protein
protects cells from apoptosis, especially that induced by
NO-compounds [31,32].
With the exception of LRWZ, all the lines evaluated in in
vitro studies showed a high tumorigenic capacity, making
it possible to evaluate in vivo the antitumor efficacy of
NCX 4040. The long-term administration of this drug was
well tolerated by the mice and reduced the tumor mass of
LoVo, LoVo Dx and WiDr lines compared to untreated
mice. Analysis of growth curves highlighted differences in
the degree of drug sensitivity between cell lines. NCX
4040 was very effective in delaying tumor growth in LoVo
tumors, whereas WiDr, and especially LoVo Dx lines,
regrew after the end of treatment. These results confirm
the in vitro data and seem to indicate that, as observed in
vitro, the ability of NCX 4040 to induce apoptosis has a
key role in the antitumor efficacy of this drug.
Conclusions
In conclusion, NCX 4040 was effective in reducing the
growth of several human colon cancer cell lines both in
vitro and in vivo, whereas the parental compound aspirin
(A) Activation of caspases-9 and -3 after exposure times of 1, 2, 3, 4, 5 and 6 h to 10 µM of NCX 4040 in LoVo cells Figure 6
(A) Activation of caspases-9 and -3 after exposure times of 1, 2, 3, 4, 5 and 6 h to 10 µM of NCX 4040 in LoVo cells. (B) Acti-
vation of caspases-9 and -3 after exposure times of 8, 10, 12 and 14 h to 50 µM of NCX 4040 in LRWZ cells. An antibody for 
actin was used as loading control.
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Antitumor efficacy in mice implanted with LoVo Dx (A), WiDr (B) and LoVo (C) cell lines Figure 7
Antitumor efficacy in mice implanted with LoVo Dx (A), WiDr (B) and LoVo (C) cell lines. Each experimental group included 8 
mice, each experiment was repeated at least three times, and representative independent experiments are reported. Experi-
mental points represent means of 24 experiments (bars, SD). Arrows indicate the start of treatment.
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showed no activity, which suggests that the NO-releasing
derivate could prove useful in the clinical management of
colon cancer, possibly in combination with conventional
antineoplastic drugs.
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